Tomáš Heizer

Dr. Tomáš Heizer

Institute of Pathological Physiology, First Faculty of Medicine, Charles University
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VPVitalii Patsula
Vitalii Patsula
DHDaniel Horak
Daniel Horak
JKJan Kučka
Jan Kučka
HMHana Mackova
Hana Mackova
VLVolodymyr Lobaz
Volodymyr Lobaz
LŠLuděk Šefc
Luděk Šefc
Magnetite (Fe3O4) nanoparticles with uniform sizes of 10, 20, and 31 nm were prepared by thermal decomposition of Fe(III) oleate or mandelate in a high-boiling point solvent (>320 °C). To render the particles with hydrophilic and antifouling properties, their surface was coated with a PEG-containing bisphosphonate anchoring group. The PEGylated particles were characterized by a range of physicochemical methods, including dynamic light scattering, transmission electron microscopy, thermogravimetric analysis, Fourier transform infrared spectroscopy, and magnetization measurements. As the particle size increased from 10 to 31 nm, the amount of PEG coating decreased from 28.5 to 9 wt.%. The PEG formed a dense brush-like shell on the particle surface, which prevented particles from aggregating in water and PBS (pH 7.4) and maximized the circulation time in vivo. Magnetic resonance relaxometry confirmed that the PEG-modified Fe3O4 nanoparticles had high relaxivity, which increased with increasing particle size. In the in vivo experiments in a mouse model, the particles provided visible contrast enhancement in the magnetic resonance images. Almost 70% of administrated 20-nm magnetic nanoparticles still circulated in the blood stream after four hours; however, their retention in the tumor was rather low, which was likely due to the antifouling properties of PEG.

20 May 2013 in Journal of Physical Organic Chemistry
Verified
Journal Article
Closed access
PDF file
ZBZuzana Barbierikova
Zuzana Barbierikova
MBMaros Bella
Maros Bella
ĽSĽudmila Sekeráková
Ľudmila Sekeráková
JLJozef Lietava
Jozef Lietava
MBMiroslava Bobeničová
Miroslava Bobeničová
VBVlasta Brezová
Vlasta Brezová

21 September 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
PKPeter Kesa
Peter Kesa
MPMonika Paúrová
Monika Paúrová
MBMichal Babič
Michal Babič
THTomáš Heizer
Tomáš Heizer
PMPetr Matouš
Petr Matouš
VHVít Herynek
Vít Herynek
Photoacoustic imaging, an emerging modality, provides supplemental information to ultrasound imaging. We investigated the properties of polypyrrole nanoparticles, which considerably enhance contrast in photoacoustic images, in relation to the synthesis procedure and to their size. We prepared polypyrrole nanoparticles by water-based redox precipitation polymerization in the presence of ammonium persulphate (ratio nPy:nOxi 1:0.5, 1:1, 1:2, 1:3, 1:5) or iron(III) chloride (nPy:nOxi 1:2.3) acting as an oxidant. To stabilize growing nanoparticles, non-ionic polyvinylpyrrolidone was used. The nanoparticles were characterized and tested as a photoacoustic contrast agent in vitro on an imaging platform combining ultrasound and photoacoustic imaging. High photoacoustic signals were obtained with lower ratios of the oxidant (nPy:nAPS ≥ 1:2), which corresponded to higher number of conjugated bonds in the polymer. The increasing portion of oxidized structures probably shifted the absorption spectra towards shorter wavelengths. A strong photoacoustic signal dependence on the nanoparticle size was revealed; the signal linearly increased with particle surface. Coated nanoparticles were also tested in vivo on a mouse model. To conclude, polypyrrole nanoparticles represent a promising contrast agent for photoacoustic imaging. Variations in the preparation result in varying photoacoustic properties related to their structure and allow to optimize the nanoparticles for in vivo imaging.

1 December 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
LLLenka Loukotová
Lenka Loukotová
JKJan Kučka
Jan Kučka
MRMariia Rabyk
Mariia Rabyk
AHAnita Höcherl
Anita Höcherl
KVKristýna Venclíková
Kristýna Venclíková
Martin HrubyMartin Hruby
Martin Hruby

29 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
EGElena Golovina
Elena Golovina
THTomáš Heizer
Tomáš Heizer
LDLenka Daumova
Lenka Daumova
MBMartin Báječný
Martin Báječný
KVKarina Savvulidi Vargova
Karina Savvulidi Vargova
Hypoxia represents one of the key factors that stimulate the growth of leukemic cells in their niche. Leukemic cells in hypoxia are forced to reprogram their original transcriptome, miRNome, and metabolome. How the coupling of miRNAs/mRNAs helps to maintain or progress the leukemic status is still not fully described. MicroRNAs (miRNAs) regulate practically all biological processes within cells and play a crucial role in leukemia development/progression. Here we worked with the human cell line MEC-1 (human chronic lymphocytic leukemia (CLL)) where we deleted mature miR-155 by CRISPR/Cas9. MEC-1 cells in hypoxia showed a higher proliferation rate with a relatively low level of apoptosis. Interestingly, miR-155 deficiency decreased the proliferation rate in both, normoxia and hypoxia. Besides common hypoxia-related genes (HIF1α, EGLN1, VHL, HK1, and HK2), we also measured, genes for glucose transporters SLC2A1 (GLUT1) and SLC2A3 (GLUT3). Surprisingly, only SLC2A3 (GLUT3) showed significant overexpression in hypoxia conditions in miR-155 deficient MEC-1cells which points to the possible novel target of miR-155 in CLL. Increased glucose uptake and decreased lactate support our hypothesis that miR-155 deficiency and hypoxia transform cell metabolism. To conclude, miR-155 deficiency and hypoxia-impaired glucose metabolism stimulate GLUT3 in CLL cells.